Drugs / TILs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04674488 | Dec 2020 → Nov 2022 | — | Shanghai OriginCell Therapeutics Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TILs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04674488 ↗ |
| Modality | Cell therapy | “adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion” NCT04674488 ↗ |